BioXcel Therapeutics Inc. (BTAI)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.83 |
Market Cap | 8.48M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -32.64 |
PE Ratio (ttm) | -0.09 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.87 |
Volume | 245,595 |
Avg. Volume (20D) | 118,620 |
Open | 2.89 |
Previous Close | 2.64 |
Day's Range | 2.74 - 3.15 |
52-Week Range | 2.56 - 61.12 |
Beta | undefined |
About BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI...
Analyst Forecast
According to 4 analyst ratings, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 1023.44% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
News

2 months ago · seekingalpha.com
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call TranscriptBioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial O...